News

“This FDA approval is another milestone in the journey for Dupixent as an innovative biologic treatment for atopic dermatitis and other conditions driven in part by type 2

The deal value of $500m will be based on the achievement of certain predetermined regulatory and commercial milestones. The transaction will provide Shionogi with global rights to Tetra’s

This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.

In this connection, Novaremed has filed an investigational new drug (IND) application to the FDA. The clinical-stage Swiss biopharma company revealed to have got initial feedback from the

An estimated 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to more than 11,000 deaths in the US in 2020.1

The IND has been submitted for a multinational phase 2b/3 study to assess re-purposed drug NP-120 (Ifenprodil) as a potential therapeutic treatment for patients with Covid-19. Ifenprodil, an

Importantly, the final trial results have also confirmed the drug’s positive effects on the secondary trial endpoints that assessed the drug’s activity and efficacy including measuring the effects

The Canadian biopharma company expects to immediately begin recruitment for the mid-stage trial of favipiravir with an aim to enroll nearly 760 subjects from both residents and staff

Nautilus’ total funding now exceeds $100 million. The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This